Principal Financial Group
CLSD

Principal Financial Group’s Clearside Biomedical CLSD Stock Holding History

Principal Financial Group’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,025
Closed -$104K – 2526
2022
Q1 		$104K Sell
3,025
-1,331
-31% -$39.8K ﹤0.01% 2422
2021
Q4 		$180K Buy
+4,356
New +$282K ﹤0.01% 2388
2020
Q4 		– Sell
-4,521
Closed -$104K – 2424
2020
Q3 		$104K Buy
4,521
+2,138
+90% +$55.3K ﹤0.01% 2263
2020
Q2 		$67K Buy
+2,383
New +$70.2K ﹤0.01% 2276

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Principal Financial Group's CLSD Position: Q2 2022 in Review

Principal Financial Group sold out of Clearside Biomedical (CLSD) in Q2 2022, closing a stake of 3,025 shares — an estimated $104K sold.

Principal Financial Group first reported a position in CLSD in Q2 2020 and held it in 4 quarters. The position peaked at $180K in Q4 2021. 53 funds tracked by Wall St. Rank hold CLSD as of Q2 2022.

  • Principal Financial Group reported no remaining Clearside Biomedical position as of Q2 2022 after selling out during the quarter.
  • Principal Financial Group sold 3,025 Clearside Biomedical shares in Q2 2022, an estimated $104K.
  • Principal Financial Group first reported a position in Clearside Biomedical in Q2 2020 and held it in 4 quarters.
  • Principal Financial Group's Clearside Biomedical position peaked at $180K in Q4 2021.
  • 53 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2022.

Based on Principal Financial Group's 13F filing for Q2 2022, filed 10 Aug 2022.